Novo Nordisk(US:NVO) Zhi Tong Cai Jing·2025-07-30 13:33Group 1 - Novo Nordisk's stock price has been declining significantly after issuing a profit warning and appointing a new CEO, resulting in a market value loss of $70 billion [2] - The company has lowered its sales growth forecast for 2025 from 13%-21% to 8%-14%, and its operating profit growth forecast from 16%-24% to 10%-16% [2] - Since the launch of Wegovy in 2021, Novo Nordisk's market value peaked at $615 billion but has since dropped by two-thirds due to concerns over losing competitive advantage in the weight loss drug market [2] Group 2 - The stock experienced a sharp decline of 23% on Tuesday, with an intraday drop of 30% [3] - The sales forecast downgrade is attributed to competition from compounded generic drugs that use the same active ingredients as the branded drug, which caught investors off guard [3] - Barclays downgraded Novo Nordisk's rating from "Overweight" to "Neutral," citing a significant credibility crisis regarding the company's assessment of its issues [3] Group 3 - Novo Nordisk is intensifying efforts to regain patients using compounded generics and has increased dialogue with the FDA to curb illegal compounded drugs [3] - JPMorgan maintained an "Overweight" rating but reduced the target price from 650 to 500 Danish kroner, indicating cautious optimism about a potential recovery in U.S. prescriptions [3]